Drug Trial Radar · NCT05795517
Study of HSK31679 in Subjects With Hypercholesterolemia With Nonalcoholic Fatty Liver Disease(NAFLD)
Last checked: Nov 20, 2026Latest source record: Apr 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
Apr 26, 2023
Primary completion
Feb 20, 2024
Study completion Mar 1, 2024
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of HSK31679 tablets compared with placebo in reducing low-density lipoprotein cholesterol (LDL-C) and MRI-PDFF after 12 weeks of treatment in patients with hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD).
Conditions
- Hypercholesterolemia
Interventions
HSK31679 low doseDrug
HSK31679 low dose and placebo of HSK31679 ,QD,oral,Day1 to week 12
HSK31679 medium doseDrug
HSK31679 medium dose and placebo of HSK31679 ,QD,oral,Day1 to week 12
HSK31679 high doseDrug
HSK31679 high dose and placebo of HSK31679 ,QD,oral,Day1 to week 12
PlaceboDrug
placebo ,QD,oral,Day1 to week 12
Ezetimibe 10mgDrug
Ezetimibe 10mg+placebo of HSK31679 ,QD,oral,Day1 to week 12
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in LDL-C from baseline at 12 week;Time frame: Baseline and Week 12
- Percentage change in MRI-PDFF from baseline at 12 week;Time frame: Baseline and Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Changgung Hospital, Tsinghua University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.